ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CLDX Celldex Therapeutics Inc

41.80
0.01 (0.02%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 579,712
Bid Price 39.69
Ask Price 43.18
News -
Day High 42.30

Low
22.11

52 Week Range

High
53.18

Day Low 41.21
Company Name Stock Ticker Symbol Market Type
Celldex Therapeutics Inc CLDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.02% 41.80 20:00:00
Open Price Low Price High Price Close Price Prev Close
41.68 41.21 42.30 41.97 41.79
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,146 579,712 $ 41.72 $ 24,185,407 - 22.11 - 53.18
Last Trade Time Type Quantity Stock Price Currency
19:05:27 formt 300 $ 41.80 USD

Celldex Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.34B 55.90M - 6.88M -141.43M -2.53 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Celldex Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CLDX Message Board. Create One! See More Posts on CLDX Message Board See More Message Board Posts

Historical CLDX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week42.7143.4240.41541.43687,790-0.91-2.13%
1 Month51.5053.1839.5046.121,234,099-9.70-18.83%
3 Months39.5253.1834.6543.19982,7392.285.77%
6 Months27.2653.1822.1136.69861,87814.5453.34%
1 Year35.0353.1822.1135.16688,1456.7719.33%
3 Years20.0157.2015.3735.11633,97621.79108.90%
5 Years5.1557.201.5024.01681,90636.65711.65%

Celldex Therapeutics Description

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Your Recent History

Delayed Upgrade Clock